Fundamental Analysis

GLAND PHARMA LTD.

Ticker : 543245
BUY: Rs 3847.05
Target: Rs 4350



Gland Pharma is one of the fastest-growing small-molecule generic injectables-focussed companies with a global footprint across 60 countries. Analysing the consolidated quarterly results, the company recorded a robust increase of 29.94 per cent in the net sales & operating income, which stood at Rs 1,080.47 crore for Q2FY22 as compared to the net sales and operating income of Rs 831.5 crore reported for Q2FY21. The operating profit for the quarter was recorded at Rs 427.80 crore in Q2FY22 as compared to the operating profit of Rs 318.05 crore posted in Q2FY21. The company reported a net profit of Rs 302.08 crore in Q2FY22 versus Rs 218.86 crore recorded in Q2FY21, a rise of 38.03 per cent. The company delivered in-line Q2FY22 results attributing to strong revenue growth across all geographies in spite of supply disruptions leading to cost pressures. Owing to the continued launch of new products, rapid geographic expansion, and volume gains in existing products, we recommend BUY.